Security
Journey Medical Corporation Common Stock · DERM
DERMNASDAQCommon stockCurrentCIK 1867066Updated Oct 12, 2026
DERM price & chart
Loading TradingView…
NASDAQ:DERM on TradingView ↗About the company
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets nine branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and the company files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
In the news
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 85,191,000Source | 64,044,000Source | 98,356,000Source | 81,158,000Source | 65,189,000Source | 91,534,000Source | 84,962,000Source | 66,571,000Source | 94,589,000Source | 80,241,000Source | 76,849,000Source | 105,160,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 28,670,000Source | 17,844,000Source | 25,510,000Source | 29,734,000Source | 18,658,000Source | 26,479,000Source | 30,798,000Source | 19,473,000Source | 27,605,000Source | 31,863,000Source | 20,287,000Source | 27,197,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 24,948,000Source | 22,461,000Source | 25,643,000Source | 20,293,000Source | 23,912,000Source | 27,219,000Source | 21,070,000Source | 24,057,000Source | 24,090,000Source | 20,305,000Source | 27,439,000Source | 32,003,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 17,983,000Source | 10,671,000Source | 36,246,000Source | 15,644,000Source | 10,465,000Source | 24,992,000Source | 18,025,000Source | 9,799,000Source | 29,783,000Source | 10,231,000Source | 15,222,000Source | 28,208,000Source |
| Inventory, NetUSD | 11,818,000Source | 11,788,000Source | 8,156,000Source | 12,852,000Source | 9,687,000Source | 9,292,000Source | 12,496,000Source | 10,580,000Source | 9,624,000Source | 14,431,000Source | 10,206,000Source | 14,159,000Source |
| Assets, CurrentUSD | 56,387,000Source | 46,162,000Source | 72,781,000Source | 51,268,000Source | 46,470,000Source | 64,967,000Source | 53,986,000Source | 47,013,000Source | 66,873,000Source | 48,179,000Source | 56,455,000Source | 77,679,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,638,000Source | 1,242,000Source | 2,736,000Source | 2,479,000Source | 2,406,000Source | 3,464,000Source | 2,395,000Source | 2,577,000Source | 3,376,000Source | 3,212,000Source | 3,588,000Source | 3,309,000Source |
| Operating Lease, Right-of-Use AssetUSD | 134,000Source | 32,000Source | 65,000Source | 156,000Source | 55,000Source | 88,000Source | 178,000Source | 79,000Source | 111,000Source | 199,000Source | 101,000Source | 189,000Source |
| Other Assets, NoncurrentUSD | — | 6,000Source | — | — | 6,000Source | — | — | 6,000Source | — | — | 6,000Source | 95,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 59,293,000Source | 53,118,000Source | 66,242,000Source | 61,912,000Source | 53,894,000Source | 60,703,000Source | 63,421,000Source | 53,620,000Source | 62,737,000Source | 60,172,000Source | 56,499,000Source | 88,178,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 123,106,000Source | 99,472,000Source | 133,111,000Source | 114,140,000Source | 97,451,000Source | 131,516,000Source | 112,639,000Source | 95,746,000Source | 130,307,000Source | 107,094,000Source | 92,703,000Source | 85,482,000Source |
| Retained Earnings (Accumulated Deficit)USD | -97,211,000Source | -88,548,000Source | -101,000,000Source | -94,896,000Source | -86,158,000Source | -100,688,000Source | -91,100,000Source | -82,797,000Source | -98,458,000Source | -87,027,000Source | -72,355,000Source | -68,502,000Source |
| Stockholders' Equity Attributable to ParentUSD | 25,898,000Source | 10,926,000Source | 32,114,000Source | 19,246,000Source | 11,295,000Source | 30,831,000Source | 21,541,000Source | 12,951,000Source | 31,852,000Source | 20,069,000Source | 20,350,000Source | 16,982,000Source |
| Liabilities and EquityUSD | 85,191,000Source | 64,044,000Source | 98,356,000Source | 81,158,000Source | 65,189,000Source | 91,534,000Source | 84,962,000Source | 66,571,000Source | 94,589,000Source | 80,241,000Source | 76,849,000Source | 105,160,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 39,715,000Source | 33,333,000Source | 45,770,000Source | 40,481,000Source | 34,146,000Source | 37,830,000Source | 40,222,000Source | 38,936,000Source | 37,442,000Source | 35,175,000Source | 41,868,000Source | 66,832,000Source |
| Operating Lease, Liability, CurrentUSD | 98,000Source | 34,000Source | 69,000Source | 96,000Source | 59,000Source | 94,000Source | 93,000Source | 84,000Source | 101,000Source | 83,000Source | 99,000Source | 83,000Source |
| Accounts Payable, CurrentUSD | 11,557,000Source | 15,339,000Source | 8,049,000Source | 12,754,000Source | 14,604,000Source | 8,202,000Source | 14,404,000Source | 15,343,000Source | 8,851,000Source | 16,050,000Source | 18,149,000Source | 36,570,000Source |
| Operating Lease, Liability, NoncurrentUSD | 44,000Source | — | — | 69,000Source | — | — | 94,000Source | — | 18,000Source | 118,000Source | 9,000Source | 108,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 21,193,000Source | 16,008,000Source | 31,831,000Source | 22,554,000Source | 15,972,000Source | 26,102,000Source | 23,011,000Source | 20,033,000Source | 27,567,000Source | 17,425,000Source | 20,350,000Source | 19,388,000Source |
| Long-term DebtUSD | 25,159,000Source | 19,785,000Source | 25,472,000Source | 25,112,000Source | 19,748,000Source | 25,373,000Source | 24,980,000Source | 14,684,000Source | 25,277,000Source | 24,879,000Source | 14,622,000Source | 27,765,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 19,534,000Source | 19,785,000Source | 20,472,000Source | 21,362,000Source | 19,748,000Source | 22,873,000Source | 23,105,000Source | 14,684,000Source | 25,277,000Source | 24,879,000Source | 14,622,000Source | 19,826,000Source |
| Long-term Debt, Current Maturities | —Source | — | —Source | —Source | — | —Source | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -2,230,000Source | -4,073,000Source | -11,431,000Source | -14,672,000Source | -3,853,000Source | -29,628,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 989,000Source | 1,323,000Source | 6,288,000Source | 6,098,000Source | 2,606,000Source | 4,425,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -4,761,000Source | 7,989,000Source | 19,341,000Source | -4,475,000Source | -12,551,000Source | 5,380,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -332,000Source | -1,935,000Source | -4,807,000Source | 4,225,000Source | -3,953,000Source | -1,744,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -649,000Source | -1,646,000Source | -7,199,000Source | -2,099,000Source | -18,421,000Source | 14,343,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 2,909,000Source | -2,832,000Source | -12,441,000Source | -9,127,000Source | 5,240,000Source | -13,534,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | -15,000,000Source | -5,000,000Source | -20,000,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 220,000Source | 3,597,000Source | 16,226,000Source | 16,993,000Source | -4,804,000Source | 16,456,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 3,129,000Source | 765,000Source | 3,785,000Source | -7,134,000Source | -4,564,000Source | -17,078,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 24,948,000Source | 22,461,000Source | 25,643,000Source | 20,293,000Source | 27,219,000Source | 21,070,000Source | 24,090,000Source | 20,305,000Source | 27,439,000Source | 32,003,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 806,000Source | 813,000Source | 3,238,000Source | 2,011,000Source | 1,127,000Source | 993,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 50,000Source | 125,000Source | 181,000Source | 168,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,854,000Source | 1,640,000Source | 1,437,000Source | 1,336,000Source | 989,000Source | 1,323,000Source | 6,288,000Source | 6,098,000Source | 2,606,000Source | 4,425,000Source |
| Amortization of Intangible AssetsUSD | — | — | 1,064,000Source | 814,000Source | 969,000Source | 1,064,000Source | 1,126,000Source | 1,065,000Source | 4,258,000Source | 3,424,000Source | 3,767,000Source | 4,277,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -3,000Source | -51,000Source | -1,000Source | -61,000Source | -3,000Source | -7,000Source | -90,000Source | -116,000Source | -183,000Source | -89,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 1,125,000Source | — | — | — | — | — | 1,125,000Source | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 3,143,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 15,000Source | 60,000Source | — | — | 60,000Source | 61,000Source | 221,000Source | 63,000Source |
| InterestExpenseNonoperatingUSD | — | — | 937,000Source | 758,000Source | 906,000Source | 937,000Source | 892,000Source | 891,000Source | 3,698,000Source | 2,700,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,315,000Source | -2,390,000Source | -312,000Source | -3,796,000Source | -2,230,000Source | -4,073,000Source | -11,431,000Source | -14,672,000Source | -3,853,000Source | -29,628,000Source |
| Nonoperating Income (Expense)USD | — | — | -786,000Source | 504,000Source | -753,000Source | -860,000Source | -738,000Source | -749,000Source | -3,199,000Source | -934,000Source | -1,559,000Source | -2,048,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | 75,000Source | 50,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 4,048,000Source | 16,359,000Source | 7,877,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 72,000Source | 75,000Source | 350,000Source | 207,000Source | 121,000Source | 142,000Source |
| Amortization of Debt Issuance Costs | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 17,025,000Source | 14,629,000Source | 17,839,000Source | 15,009,000Source | 15,921,000Source | 13,139,000Source | 61,239,000Source | 55,134,000Source | 59,662,000Source | 70,995,000Source |
| Cost of Goods and Services Sold | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 12,054,000Source | 11,396,000Source | 10,888,000Source | 11,882,000Source | 10,109,000Source | 10,569,000Source | 44,368,000Source | 40,204,000Source | 43,910,000Source | 59,468,000Source |
| Operating Income (Loss)USD | — | — | -1,529,000Source | -2,894,000Source | 456,000Source | -2,876,000Source | -1,492,000Source | -3,324,000Source | -8,172,000Source | -13,677,000Source | -2,073,000Source | -27,517,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -2,315,000Source | -2,390,000Source | -297,000Source | -3,736,000Source | -2,230,000Source | -4,073,000Source | -11,371,000Source | -14,611,000Source | -3,632,000Source | -29,565,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 15,000Source | 60,000Source | — | — | 60,000Source | 61,000Source | 221,000Source | 63,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,315,000Source | -2,390,000Source | -312,000Source | -3,796,000Source | -2,230,000Source | -4,073,000Source | -11,431,000Source | -14,672,000Source | -3,853,000Source | -29,628,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.09Source | -0.12Source | -0.01Source | -0.16Source | -0.08Source | -0.18Source | -0.47Source | -0.72Source | -0.21Source | -1.69Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.09Source | -0.12Source | -0.01Source | -0.16Source | -0.08Source | -0.18Source | -0.47Source | -0.72Source | -0.21Source | -1.69Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 24,959,114Source | 20,537,794Source | 27,493,693Source | 23,290,806Source | 27,305,028Source | 22,611,040Source | 24,497,973Source | 20,431,400Source | 18,232,422Source | 17,531,274Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 24,959,114Source | 20,537,794Source | 27,493,693Source | 23,290,806Source | 27,305,028Source | 22,611,040Source | 24,497,973Source | 20,431,400Source | — | 17,531,274Source |
| Interest Expense (non-operating)USD | — | — | 937,000Source | 758,000Source | 906,000Source | 937,000Source | 892,000Source | 891,000Source | 3,698,000Source | 2,700,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 1,064,000Source | 814,000Source | 969,000Source | 1,064,000Source | 1,126,000Source | 1,065,000Source | 4,258,000Source | 3,424,000Source | 3,767,000Source | 4,277,000Source |
| Costs and ExpensesUSD | — | — | 19,160,000Source | 17,523,000Source | 18,054,000Source | 17,885,000Source | 17,453,000Source | 16,463,000Source | 70,030,000Source | 69,811,000Source | 81,254,000Source | 101,186,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -3,000Source | -51,000Source | -1,000Source | -61,000Source | -3,000Source | -7,000Source | -90,000Source | -116,000Source | -183,000Source | -89,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,698,000Source | 2,019,000Source |
| Interest Expense, DebtUSD | — | — | 814,000Source | 671,000Source | 906,000Source | 937,000Source | 892,000Source | 891,000Source | 3,698,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -786,000Source | 504,000Source | -753,000Source | -860,000Source | -738,000Source | -749,000Source | -3,199,000Source | -934,000Source | -1,559,000Source | -2,048,000Source |
| Other IncomeUSD | — | — | 606,000Source | — | 671,000Source | — | 40,000Source | — | 619,000Source | 1,000,000Source | 19,519,000Source | 2,674,000Source |
| Research and Development ExpenseUSD | — | — | 287,000Source | 842,000Source | 54,000Source | — | — | 39,000Source | 480,000Source | 9,857,000Source | 7,541,000Source | 10,943,000Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | —Source | —Source | — | —Source | — | —Source | — | — | — | — |
Offerings
Registration 333-292758
Filing attachments
tm2622742d1_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 tm2622742d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi ® revenues were $8.1 million for the second quarter of 2026 Strong revenue growth and disciplined cost management continue drive to profitability Company to hold conference call today at 4:30 p.m. ET Sc…
Read attachment ↗tm2614268d1_ex99-1.htm · 8-K · 2026-05-13
EX-99.1 2 tm2614268d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET Scottsdale,…
Read attachment ↗tm2612310d1_ex99-1.htm · 8-K · 2026-04-21
EX-99.1 2 tm2612310d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™ Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Scottsdale, AZ - April 21, 2026 - Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on developing, selling an…
Read attachment ↗tm269707d1_ex99-1.htm · 8-K · 2026-03-25
EX-99.1 2 tm269707d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi TM generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi TM during FY2025 Payer access for Emrosi TM available to over 100 million…
Read attachment ↗tm2534369d2_ex4-7.htm · S-3 · 2026-01-15
Exhibit 4.7 JOURNEY MEDICAL CORPORATION and Trustee INDENTURE Dated as of_______________ SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act Section of of 1939, as amended Indenture ──────────────────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) Inappl…
Read attachment ↗tm2534369d2_ex4-8.htm · S-3 · 2026-01-15
Exhibit 4.8 JOURNEY MEDICAL CORPORATION and Trustee INDENTURE Dated as of_______________ SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act Section of of 1939, as amended Indenture ───────────────────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) …
Read attachment ↗